DB-3Q for Medically Refractory Crohn's Disease
This study is looking into DB-3Q as a potential treatment for Crohn's disease that hasn't responded well to other therapies. DB-3Q is a product made from bone marrow stem cells. Researchers want to see if DB-3Q is safe and effective compared to a placebo (a salt water solution). You might be able to join if you are 18-75 years old and have Crohn's disease for at least six months that hasn't improved with at least one advanced immune therapy. The main goal is to see how much your Crohn's disease symptoms improve after 12 weeks, measured by a score called SES-CD. The current status of this study is unclear, and it plans to enroll 36 participants.
- Study design
- This study is an interventional trial comparing DB-3Q to a placebo. It plans to enroll 36 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 12 weeks, suggesting follow-up for at least that long.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
DB-3Q for the Treatment of Medically Refractory Crohn's Disease
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change from baseline in SES-CD Score12 Weeks
Simple Endoscopic Score for Crohn's Disease (SES-CD) is a standardized tool used by gastroenterologists to assess and quantify the severity of Crohn's disease during an endoscopy or colonoscopy. The scale goes from 0 to greater than 15, with a lower score being better.